{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:54:10Z","timestamp":1790967250000,"version":"4.1.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Rhabdomyolysis is a clinical syndrome characterized by the breakdown of skeletal muscle, leading to the release of creatine kinase (CK), myoglobin and electrolytes into the circulation. This can result in acute kidney injury and other complications. Common etiologies include trauma, medications and metabolic disorders. We report a case of semaglutide-associated rhabdomyolysis in a 36-year-old obese male who presented with bilateral lower extremity pain, cramping and dark urine 6\u00a0days after increasing his weekly dose from 1.7\u00a0mg to 2.4\u00a0mg. The dose had been titrated weekly from 0.25\u00a0mg to 1.0\u00a0mg, then to 1.7\u00a0mg, and finally to 2.4\u00a0mg. Laboratory evaluation revealed markedly elevated CK (16\u2009202\u00a0U\/L; normal: 20\u2013200\u00a0U\/L) and liver enzymes (aspartate aminotransferase: 279\u00a0U\/L, alanine aminotransferase: 77\u00a0U\/L), consistent with rhabdomyolysis. After excluding other common causes through clinical assessment and diagnostic workup, this case underscores the importance of recognizing this rare but potentially serious adverse effect of semaglutide.<\/jats:p>","DOI":"10.1093\/ckj\/sfaf356","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T13:31:01Z","timestamp":1763731861000},"source":"Crossref","is-referenced-by-count":4,"title":["From weight loss to muscle loss: rhabdomyolysis linked to semaglutide"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3926-7288","authenticated-orcid":false,"given":"Rutvikkumar","family":"Jadvani","sequence":"first","affiliation":[{"name":"University of Utah School of Medicine Department of General Internal Medicine, , Salt Lake City, UT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3609-0075","authenticated-orcid":false,"given":"Meenu","family":"Singh","sequence":"additional","affiliation":[{"name":"University of Utah School of Medicine Department of General Internal Medicine, , Salt Lake City, UT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"key":"2025121003314737200_bib1","first-page":"272","article-title":"Rhabdomyolysis: a review of the literature","volume":"67","author":"Khan","year":"2009","journal-title":"Neth J Med"},{"key":"2025121003314737200_bib2","volume-title":"StatPearls [Internet]","author":"Stanley","year":"2024"},{"key":"2025121003314737200_bib3","doi-asserted-by":"publisher","first-page":"101015","DOI":"10.1016\/j.disamonth.2020.101015","volume":"66","author":"Cabral","year":"2020","journal-title":"Dis Mon"},{"key":"2025121003314737200_bib4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.tcm.2021.12.008","article-title":"Semaglutide for the treatment of obesity","volume":"33","author":"Chao","year":"2023","journal-title":"Trends Cardiovasc Med"},{"key":"2025121003314737200_bib5","doi-asserted-by":"publisher","first-page":"645563","DOI":"10.3389\/fendo.2021.645563","article-title":"Safety of semaglutide","volume-title":"Front Endocrinol (Lausanne)","author":"Smits","year":"2021"},{"key":"2025121003314737200_bib6","doi-asserted-by":"publisher","first-page":"e50227","DOI":"10.7759\/cureus.50227","article-title":"Rhabdomyolysis associated with semaglutide therapy: a case report","volume":"15","author":"Billings","year":"2023","journal-title":"Cureus"},{"key":"2025121003314737200_bib7","doi-asserted-by":"publisher","DOI":"10.48448\/0y21-qn46","author":"de la Cova","year":"2024","journal-title":"Losing Fat or Muscle? A Case of Rhabdomyolysis Following Initiation of Semaglutide (Wegovy), AMA Research Challenge 2024"},{"key":"2025121003314737200_bib8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13054-016-1314-5","article-title":"Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice","volume":"20","author":"Chavez","year":"2016","journal-title":"Crit Care"},{"key":"2025121003314737200_bib9","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1515\/cclm-2023-0313","article-title":"Safety monitoring of drug-induced muscle injury and rhabdomyolysis: a biomarker-guided approach for clinical practice and drug trials","volume":"61","author":"Ostrowski","year":"2023","journal-title":"Clin Chem Lab Med"},{"key":"2025121003314737200_bib10","doi-asserted-by":"publisher","first-page":"102427","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: a systematic review of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"2025121003314737200_bib11","volume-title":"StatPearls [Internet]","author":"Kommu","year":"2024"},{"key":"2025121003314737200_bib12","doi-asserted-by":"publisher","first-page":"14514","DOI":"10.3390\/cimb46120872","article-title":"Spotlight on the mechanism of action of semaglutide","volume":"46","author":"Papakonstantinou","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"2025121003314737200_bib13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.4239\/wjd.v4.i5.190","article-title":"Effects of glucagon-like peptide-1 receptor agonists on renal function","volume":"4","author":"Filippatos","year":"2013","journal-title":"World J Diabetes"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf356\/65477690\/sfaf356.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/12\/sfaf356\/65477690\/sfaf356.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/12\/sfaf356\/65477690\/sfaf356.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T08:31:52Z","timestamp":1765355512000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfaf356\/8340371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf356","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,22]]},"article-number":"sfaf356"}}